NIH unveils new asthma guidelines

New asthma treatment guidelines could be good news for drug companies. The government advises better day-to-day control of the disease--and that probably means more widespread use of inhaled corticosteroid drugs such as Flovent (GlaxoSmithKline), Azmacort (Sanofi-Aventis), and Pulmicort (AstraZeneca).

For patients with severe asthma, the National Institutes of Health report also recommends Omalizumab, a Genentech/Novartis drug sold under the brand name Xolair, which targets antibodies that can cause asthma symptoms.

- see the new NIH guidelines
- read the Washington Post's take
- and check out this piece on AstraZeneca's asthma drugs

Related Articles:
Scientists find link between colds and asthma attacks. Report
FDA rejects GSK's Advair for COPD. Report
NIH budget cuts cause alarm in research circles. Report

Suggested Articles

Pfizer plans to sell two assets to its Mylan-Upjohn spinoff, adding $598 million in revenues—but that won't do much for its profits, analysts warned.

AstraZeneca has made a hefty investment in Brilinta with billions in R&D costs. But will that sunk cost ever turn a profit for the British drugmaker?

Novartis hopes to remove a clinical hold on the high dose of an intrathecal form of Zolgensma but expects a filing based just on the lower doses.